Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Correction

This article was originally published in The Tan Sheet

Executive Summary

In the article "Prevacid Initial Launch Efforts To Focus On Switching Prescription Users," (1"The Tan Sheet" May 18, 2009, p. 3), we inadvertently implied that Novartis intends to market Prevacid 24HR to current users of prescription Prevacid for gastroesophageal reflux disease. We should have said the firm aims to market Prevacid 24HR to the subset of its Rx patients that suffer from frequent heartburn. "The Tan Sheet" regrets the misstatement

You may also be interested in...



Prevacid Initial Launch Efforts To Focus On Switching Prescription Users

Novartis plans to prioritize converting patients currently treated with prescription Prevacid when the proton pump inhibitor becomes available over-the-counter, rather than winning over Prilosec OTC users, a Novartis executive said

Salus Adds Two Floradix Lines In The UK, Including Immunity Booster

Salus Haus has expanded its popular Floradix range with an immunity boosting liquid supplement and a children's verison of its flagship Floradix Liquid product. 

GSK Raises Product Prices in US And Europe As Costs Rise

GSK revealed price increases in the US, Europe and China as it posted Q3 sales up high single-digits, with gains in key categories such as pain relief and vitamins, minerals and supplements.

Topics

UsernamePublicRestriction

Register

PS102938

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel